Drug combination ‘boosts therapy success’ in Crohn’s disease
New studies provide clarity on the benefits of using the monoclonal antibody vedolizumab plus thiopurines in inflammatory bowel disease
Vedolizumab in combination with thiopurines is less likely to result in treatment failure than vedolizumab alone for Crohn’s disease — but not ulcerative colitis, a study shows.
In their report on the first population-based study of its kind, US researchers say their findings will help guide clinical decision-making in patients with inflammatory bowel disease (IBD) starting biologic therapy.
